Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Tuesday, August 20, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

August 20, 2024
in News
Reading Time: 3 mins read
A A
Eli Lilly weight loss drug cuts risk of developing diabetes in trial
0
SHARES
ShareShareShareShareShare

Eli Lilly weight loss drug cuts risk of developing diabetes in trial

Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. 

The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes drug Mounjaro, also found that patients experienced sustained weight loss over the roughly three-year treatment period. Adults on the highest weekly dose of the drug saw a 22.9% decrease in body weight on average after 176 weeks, compared with 2.1% for those who received a placebo. 

The results suggest that Eli Lilly’s treatment could meaningfully delay a potential diagnosis for people with prediabetes, or those with blood sugar levels that are higher than normal but not high enough to be classified as Type 2 diabetes. 

More than 1 in 3 Americans have prediabetes, according to the latest government data, which health experts say can be reversed with lifestyle changes such as diet and exercise. People who are overweight or have obesity are at a higher risk for prediabetes. 

The new data also shows the potential long-term health benefits of taking a buzzy class of obesity and diabetes medications called GLP-1s, which mimic hormones produced in the gut to tamp down appetite and regulate blood sugar. As Eli Lilly’s Zepbound and Mounjaro and injections from rival Novo Nordisk have skyrocketed in popularity over the last two years, the companies have raced to study other clinical uses for their drugs.

“Obesity is a chronic disease that puts nearly 900 million adults worldwide at an increased risk of other complications such as Type 2 diabetes,” Dr. Jeff Emmick, senior vice president of product development at Eli Lilly, said in a statement. “These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and pre-diabetes.”

Eli Lilly tested tirzepatide in more than 1,000 adults over 176 weeks in the phase three trial, followed by a 17-week period where patients stopped treatment. It is the longest completed study on the drug to date, according to the company. 

More CNBC health coverage

The drugmaker will submit the latest results to a peer-reviewed journal and present them at an upcoming medical conference in November. Eli Lilly published 72-week weight loss results on a larger group of patients from the same trial, called SUMOUNT-1, back in 2022. 

Patients in the trial who stopped taking tirzepatide during the 17 weeks began to regain weight and saw an increase in progression to diabetes. But those participants still had an 88% lower risk of developing diabetes compared with a placebo, according to the latest phase three results.

The safety data on tirzepatide during the trial was consistent with previous studies on the drug, according to Eli Lilly. The most common side effects were gastrointestinal, such as diarrhea, nausea, constipation and vomiting, and were generally mild to moderate in severity.

Eli Lilly’s Zepbound works by imitating two naturally produced gut hormones called GLP-1 and GIP. 

GLP helps reduce food intake and appetite. GIP, which also suppresses appetite, may also improve how the body breaks down sugar and fat.

Don’t miss these insights from CNBC PRO

Watch CNBC's full interview with Eli Lilly CEO David Ricks

Credit: Source link

READ ALSO

Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?

Global commodities’ biggest winners and losers this year

ShareTweetSendSharePin
Previous Post

‘Troubling’ part of Sam Ponder’s ESPN firing

Next Post

Apple’s 13-inch iPad Air M2 drops to a record-low price

Related Posts

Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?
News

Who is Mike Lynch, UK tech entrepreneur missing in superyacht sinking?

August 20, 2024
Global commodities’ biggest winners and losers this year
News

Global commodities’ biggest winners and losers this year

August 20, 2024
Travel is too expensive now — travel demand falls under cost concerns
News

Travel is too expensive now — travel demand falls under cost concerns

August 20, 2024
3 red flags that you and your friend should not travel together
News

3 red flags that you and your friend should not travel together

August 20, 2024
Google IPO banker tracks two-decade journey from Silicon Valley upstart to  trillion
News

Google IPO banker tracks two-decade journey from Silicon Valley upstart to $2 trillion

August 19, 2024
SEC charges Carl Icahn with hiding billions worth of stock pledges
News

SEC charges Carl Icahn with hiding billions worth of stock pledges

August 19, 2024
Next Post
Apple’s 13-inch iPad Air M2 drops to a record-low price

Apple's 13-inch iPad Air M2 drops to a record-low price

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Elon Musk backs down from  million a month pledge to Trump: ‘I don’t subscribe to cult of personality’

Elon Musk backs down from $45 million a month pledge to Trump: ‘I don’t subscribe to cult of personality’

July 23, 2024
How intermittent fasting can boost energy, productivity, and work performance

How intermittent fasting can boost energy, productivity, and work performance

August 11, 2024
Jets want — and need — to see one player much less

Jets want — and need — to see one player much less

August 3, 2024
Schumer says a crypto bill can pass Senate this year; Dems join ‘Crypto4Harris’ call

Schumer says a crypto bill can pass Senate this year; Dems join ‘Crypto4Harris’ call

August 15, 2024
Student Food Innovators Win Prestigious Product Development and Research Competitions at IFT FIRST

Student Food Innovators Win Prestigious Product Development and Research Competitions at IFT FIRST

August 2, 2024
Amex is using Olivia Rodrigo concerts to tap Gen Zers in Europe

Amex is using Olivia Rodrigo concerts to tap Gen Zers in Europe

August 19, 2024
Outdated Systems, Open Doors: The Dangers of Unpatched Software in CPG Environments

Outdated Systems, Open Doors: The Dangers of Unpatched Software in CPG Environments

August 15, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Apple’s 13-inch iPad Air M2 drops to a record-low price
  • Eli Lilly weight loss drug cuts risk of developing diabetes in trial
  • ‘Troubling’ part of Sam Ponder’s ESPN firing
  • Elon Musk’s litigation strategy is about ‘punishing defendants for their speech’

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In